Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

YEN-SHEN LUIm S.-A.Colleoni M.Franke F.Bardia A.Cardoso F.Harbeck N.Hurvitz S.Chow L.Sohn J.Lee K.S.Campos-Gomez S.Vazquez R.V.Jung K.H.Babu K.G.Wheatley-Price P.De Laurentiis M.Im Y.-H.Kuemmel S.El-Saghir N.O'Regan R.Gasch C.Solovieff N.Wang C.Wang Y.Chakravartty A.Ji Y.Tripathy D.2022-09-022022-09-0220221078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-85125729661&doi=10.1158%2f1078-0432.CCR-21-3032&partnerID=40&md5=f39080fc81be2837dd5268dd583935abhttps://scholars.lib.ntu.edu.tw/handle/123456789/617769[SDGs]SDG3Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trialjournal article10.1158/1078-0432.CCR-21-3032349659452-s2.0-85125729661